 C-Peptide
"C-Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.
| Descriptor ID |
D002096
|
| MeSH Number(s) |
D06.472.699.587.200.500.250 D12.644.548.586.200.500.250
|
| Concept/Terms |
C-Peptide- C-Peptide
- C Peptide
- Connecting Peptide
- Proinsulin C-Peptide
- Proinsulin C Peptide
- C-Peptide, Proinsulin
- C Peptide, Proinsulin
|
Below are MeSH descriptors whose meaning is more general than "C-Peptide".
Below are MeSH descriptors whose meaning is more specific than "C-Peptide".
This graph shows the total number of publications written about "C-Peptide" by people in this website by year, and whether "C-Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 2 | 3 | | 1992 | 0 | 1 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2007 | 2 | 1 | 3 | | 2009 | 0 | 3 | 3 | | 2010 | 1 | 5 | 6 | | 2011 | 1 | 2 | 3 | | 2012 | 3 | 2 | 5 | | 2013 | 3 | 5 | 8 | | 2014 | 1 | 3 | 4 | | 2015 | 3 | 4 | 7 | | 2016 | 1 | 6 | 7 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 7 | 10 | | 2019 | 0 | 3 | 3 | | 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "C-Peptide" by people in Profiles.
-
Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med. 2020 11 19; 383(21):2007-2017.
-
Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeau KJ, Hao W, Clements MA, Sherr JL, Pratley RE, Hannon TS, Shah VN, Miller KM, Greenbaum CJ. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest. 2020 04 01; 130(4):1850-1862.
-
Brehm B, Summer S, Jenkins T, D'Alessio D, Inge T. Thermic effect of food and resting energy expenditure after sleeve gastrectomy for weight loss in adolescent females. Surg Obes Relat Dis. 2020 May; 16(5):599-606.
-
Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886.
-
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on ß-Cell Function: Comparison of Responses In Youth And Adults. Diabetes. 2019 08; 68(8):1670-1680.
-
Lack of Durable Improvements in ß-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2019 09; 42(9):1742-1751.
-
Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes. 2019 06; 68(6):1267-1276.
-
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019 04; 62(4):655-664.
-
Perng W, Tang L, Song PXK, Tellez-Rojo MM, Cantoral A, Peterson KE. Metabolomic profiles and development of metabolic risk during the pubertal transition: a prospective study in the ELEMENT Project. Pediatr Res. 2019 02; 85(3):262-268.
-
Evans-Molina C, Sims EK, DiMeglio LA, Ismail HM, Steck AK, Palmer JP, Krischer JP, Geyer S, Xu P, Sosenko JM. ß Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight. 2018 08 09; 3(15).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|